These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38820071)

  • 1. MetALD: Does it require a different therapeutic option?
    Marek GW; Malhi H
    Hepatology; 2024 May; ():. PubMed ID: 38820071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
    Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
    Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence.
    Ciardullo S; Mantovani A; Morieri ML; Muraca E; Invernizzi P; Perseghin G
    Liver Int; 2024 Apr; ():. PubMed ID: 38597738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    Marti-Aguado D; Calleja JL; Vilar-Gomez E; Iruzubieta P; Rodríguez-Duque JC; Del Barrio M; Puchades L; Rivera-Esteban J; Perelló C; Puente A; Gomez-Medina C; Escudero-García D; Serra MA; Bataller R; Crespo J; Arias-Loste MT
    J Hepatol; 2024 Jul; ():. PubMed ID: 38971533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort.
    Oh JH; Ahn SB; Cho S; Nah EH; Yoon EL; Jun DW
    J Hepatol; 2024 Jun; ():. PubMed ID: 38879175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
    Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD
    Hepatology; 2024 May; ():. PubMed ID: 38739848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: a nationwide study.
    Yun B; Park H; Ahn SH; Oh J; Kim BK; Yoon JH
    Am J Gastroenterol; 2024 Jun; ():. PubMed ID: 38934496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
    Ochoa-Allemant P; Marrero JA; Serper M
    Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
    Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
    Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
    Moon JH; Jeong S; Jang H; Koo BK; Kim W
    EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
    Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
    Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.
    Xie C; Alkhouri N; Elfeki MA
    World J Hepatol; 2024 May; 16(5):731-750. PubMed ID: 38818288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
    Loomba R; Wong VW
    Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.
    Lee CM; Yoon EL; Kim M; Kang BK; Cho S; Nah EH; Jun DW
    Hepatology; 2024 Jun; 79(6):1393-1400. PubMed ID: 38100294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Lee HH; Lee HA; Kim EJ; Kim HY; Kim HC; Ahn SH; Lee H; Kim SU
    Gut; 2024 Feb; 73(3):533-540. PubMed ID: 37907259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
    J Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38629681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.